UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 23

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

23
TI
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
AU
Marin D, Goldman JM, Olavarria E, Apperley JF
SO
Blood. 2003;102(7):2702.
 
AD
PMID